Consolidation of AML therapy with autograft and allograft procedures does not negate the poor prognostic impact of FLT3 internal tandem duplications: Results from the UK MRC AML 10 & 12 Trials

PD Kottaridis; RE Gale; Martin Holt; Keith Wheatley; AH Goldstone; AK Burnett; DC Linch

Consolidation of AML therapy with autograft and allograft procedures does not negate the poor prognostic impact of FLT3 internal tandem duplications: Results from the UK MRC AML 10 & 12 Trials

PD Kottaridis, RE Gale, Martin Holt, Keith Wheatley, AH Goldstone, AK Burnett, DC Linch

Cancer Clinical Trials Unit

Research output: Contribution to conference (unpublished) › Paper

Original language	English
Pages	75a Abs 273
Publication status	Published - 1 Jan 2002

Cite this

@conference{7ea81f00ec90429da1850a8d6d154bd3,

title = "Consolidation of AML therapy with autograft and allograft procedures does not negate the poor prognostic impact of FLT3 internal tandem duplications: Results from the UK MRC AML 10 & 12 Trials",

author = "PD Kottaridis and RE Gale and Martin Holt and Keith Wheatley and AH Goldstone and AK Burnett and DC Linch",

year = "2002",

month = jan,

day = "1",

language = "English",

pages = "75a Abs 273",

}

TY - CONF

T1 - Consolidation of AML therapy with autograft and allograft procedures does not negate the poor prognostic impact of FLT3 internal tandem duplications: Results from the UK MRC AML 10 & 12 Trials

AU - Kottaridis, PD

AU - Gale, RE

AU - Holt, Martin

AU - Wheatley, Keith

AU - Goldstone, AH

AU - Burnett, AK

AU - Linch, DC

PY - 2002/1/1

Y1 - 2002/1/1

M3 - Paper

SP - 75a Abs 273

ER -